Charles Duncan

Why This Cassava Sciences Analyst Is Dropping Coverage
Why This Anavex Life Sciences Analyst Is Lifting Their Price Target
Novavax Analysts Confident As Coronavirus Vaccine Candidate Heads To Phase 3 Study
Why This Anavex Life Sciences Analyst Is Lifting Their Price Target
Novavax Analysts Confident As Coronavirus Vaccine Candidate Heads To Phase 3 Study
Novavax Analyst Says Coronavirus Vaccine 'Promising': 6 Takeaways From Phase 1 Results
Why This Inovio Analyst Is Reducing Estimates For The Coronavirus Vaccine Developer

Charles Duncan Recent News

Novavax Analyst Sees Leading Contender In Coronavirus Vaccine Race
Novavax, Inc.
Inovio Analysts Project About 24% Upside Potential Amid Optimism On Coronavirus DNA Vaccine
Coronavirus vaccine play Inovio Pharmaceuticals Inc (NASDAQ: INO) announced the completion of enrollment in the Phase 1 trial of its COVID-19 DNA vaccine INO-4800 and
A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio
Among the six coronavirus vaccine candidates that have entered human trials, two belong to publicly listed U.S.
10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus Fades
GW Pharma's Epidiolex Label Expansion, EU Launch Key Growth Drivers In 2020
Aimmune Analysts Bullish On Strong Uptake Of Peanut Allergy Drug Palforzia
Analysts Remain Upbeat On GW Pharma's Optionality With Epidiolex
Cantor Fitzgerald's 7 Buys For 7 Biotechs
Acadia's FDA Breakthrough Designation For Pimavanserin Draws Mixed Response
Zynerba's Recent Results Revitalize The Bull Case, But Risks Remain
The Street May Be Underappreciating Alder Biopharma's Phase 3 Data
Piper Jaffray Defends Alder Despite Stock Slump, Looks To What's Next In Migraine Management
Piper Jaffray Sees Strength In Geron After News Of Drug Development
On Wall Street, Questions Remain For Conatus Pharma
Acadia Pharma May No Longer Be A Buy Ahead Of NDA Filing
Why Piper Jaffray's Charles Duncan Still Likes Catalyst Pharmaceuticals
Shares of Vivus Fall +10% Following Piper Jaffray's Downgrade
Geron Revealed Positive Imetelstat Results Amidst Data Concerns

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved